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A full-length molecular clone of bovine leukemia virus (BLV) pBLV-IF with two copies of a long terminal repeat (LTR) was
constructed from a previously isolated, covalently closed, circular DNA clone, pB6490, that has one copy of the LTR and the
pX region split at an EcoRI site. This molecular clone directed the synthesis of viral proteins and the induction of syncytia
in transiently transfected cells. In addition, virus particles were released into the culture medium. Serial passages of transient
transfectants also resulted in propagation of BLV. After transfection of five cell lines with linearized pBLV-IF and a
neomycin-resistance gene, BLV-producing transfectants were established in cell lines COS-1 and 23CLN that did not form
syncytia upon expression of BLV. In HeLa and FLK cells, BLV produced by a stable COS-1 transfectant was transmitted by
both cell-free and cell-to-cell infection. Thus, pBLV-IF encoded an infectious provirus that successfully induced primary and
secondary infections. This study indicates that the infectious molecular clone and the virus-producing transfectants could be
useful for further examination of the biological properties of BLV. © 1998 Academic Press
INTRODUCTION
Bovine leukemia virus (BLV), a retrovirus related to
human T-cell leukemia viruses types 1 and 2 (HTLV-1 and
HTLV-2), causes enzootic bovine leukosis (EBL), a dis-
ease characterized by a very extended course that often
involves persistent lymphocytosis (PL) and culminates in
B-cell lymphoma (Burny et al., 1980). BLV has been con-
sidered a B-lymphotropic virus in view of the absolute
increase in numbers of B lymphocytes in PL (Kumar et
al., 1978; Esteban et al., 1985), the B-lymphocyte pheno-
type of the majority of cells that form lymphosarcomas
(Onuma et al., 1978; Heeney and Valli, 1990), and the
identification of the viral antigen expressed in B lympho-
cytes after culture of peripheral blood mononuclear leu-
kocytes (Paul et al., 1977a,b). However, CD4-positive T
lymphocytes, CD8-positive T lymphocytes, monocytes,
and granulocytes can also harbor integrated BLV proviral
DNA (Williams et al., 1988; Stott et al., 1991; Schwartz et
al., 1994). Under experimental conditions, sheep can
easily be infected with BLV, and some develop B-cell
leukemia/lymphosarcoma at higher frequencies and af-
ter a shorter latent period than cattle (Djilali et al., 1987;
Aida et al., 1989). It is of interest that the transformed
phenotype of B lymphocytes that is the target of BLV is
CD52 in sheep (Murakami et al., 1994a,b; Schwartz et al.,
1994), whereas it is CD51 in cattle (Aida et al., 1993;
Schwartz et al., 1994). In contrast to in vivo infection,
BLV-infected B lymphocytes have never been estab-
lished after coculture with BLV-infected cells or inocula-
tion with cell-free BLV preparation. However, several
immortal B-cell lines have been established from tumor
cells and peripheral leukemic lymphocytes of BLV-in-
fected hosts with lymphosarcoma (Kettmann et al., 1985;
Onuma et al., 1987; Itohara et al., 1987; Koyama et al.,
1992). Infections in vitro of other types of cells, including
cells of chiropteran, canine, feline, ovine, bovine, and
murine origin, have been reported (Graves and Ferrer,
1976; Van der Matten and Miller, 1976; Derse and
Martarano, 1990), although such infections have only
rarely resulted in the establishment of cell lines that
continuously produce substantial amounts of virus. In
most cases, production of BLV is low and often de-
creases over time. Furthermore, there is no in vitro trans-
formation system for BLV analogous to T-cell transforma-
tion by HTLV-1. Indeed, to date only two BLV-producing
cell lines have been established, from the fetal lamb
kidney (FLK/BLV) (Van der Matten and Miller, 1976) and
the bat lung (Tb1Lu/BLV) (Graves and Ferrer, 1976). In
addition, expression of BLV is highly restricted both in
vivo and in vitro and is regulated at the transcriptional
and posttranscriptional levels by inducible cellular tran-
scription factors and the products of the viral tax and rex
genes (Derse, 1987; Katoh et al., 1987; Willems et al.,
1987; Derse, 1988). An infectious molecular clone is re-
quired to allow us to perform mutagenesis experiments
to investigate the role of individual gene products in the
life cycle or in the transformational potential of BLV.
Molecular clones of BLV have been shown to induce
syncytia and to produce infectious virus in vitro (Itohara
and Sekikawa, 1987; Rovnak et al., 1993), and they have
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been used to infect sheep with induction of disease
(Willems et al., 1992; Rovnak et al., 1993). The in vivo
behavior of modified viruses obtained by mutagenesis of
infectious molecular clones was analyzed in sheep (Wil-
lems et al., 1994, 1995). These studies were conducted in
advance of molecular genetic studies of infectivity and
replication of BLV in vitro because of the lack of repre-
sentative stably transfected cells that harbor a BLV mo-
lecular clone and release virions that can infect cell lines
in vitro.
As a step toward propagating BLV in various cell
cultures, we constructed an infectious full-length molec-
ular clone of BLV. This clone, pBLV-IF, carries two long
terminal repeats (LTRs) and is derived from pB6490,
which has a pX region that is split at an EcoRI site and
only one LTR (Itohara and Sekikawa, 1987). It is difficult
to develop in vitro infection and transformation systems
of B lymphocytes, which are the natural target cells for
BLV; however, by using various nonlymphoid monolayer
cell lines we analyzed the biological activity of this clone
and also established stable BLV-producing transfectants
that produced virus in sufficient quantities for subse-
quent infection experiments. Finally, to examine in detail
the infection by BLV, we tested the ability of pBLV-IF to
mediate transmission in a variety of cell types. This study
was designed to reveal those biological aspects of BLV
required for passage and propagation of the virus in
tissue culture.
RESULTS
Construction of an infectious full-length molecular
clone pBLV-IF
As shown in Fig. 1, a full-length molecular clone of BLV,
pBLV-IF, was constructed from the pB6490, which was
known as a BLV covalently closed circular DNA molecule
of 8.3-kb and was cloned in the plasmid vector pUC12.
For examination of the biological activity of pB6490 in
DNA transfection experiments, the proviral insert has to
be excised from the recombinant plasmid by digestion by
EcoRI and circularized by T4 DNA ligase since BLV in
pB6490 is split in the pX region and there is only one
copy of an LTR. The pB6490 also cannot generate a
linearized DNA that is capable of synthesizing a com-
plete BLV product and production of a stable transfec-
tant. Therefore, to avoid these disadvantages, we modi-
fied pB6490 in order to include the full open reading
frame of the pX region and two copies of an LTR. The
1.3-kb EcoRI–PstI fragment containing the 39 portion of
the pX region and the LTR of pB6490 was placed at the
EcoRI site of the 8.3-kb proviral insert which was re-
cloned in the plasmid vector pBluescript. The resulting
construct was designated pBLV-IF. An additional advan-
tage is that this clone could be purified to give high
yields from cultures of the E. coli XL1-Blue MRF9, as host,
without any deletions of the insert. In contrast, full-length
molecular clones of HTLV-1 could be propagated in a
plasmid vector only upon deletion of a portion of the 59
LTR U3 and the 39 LTR U5 (Kimata et al., 1994; Derse et
al., 1995).
Biological relevance of pBLV-IF
To examine the biological relevance of pBLV-IF, the
construct was used to transiently transfect various cell
lines, such as HeLa, NIH3T3, FLK, COS-1, and 23CLN.
Between 60 and 72 h after transfection, bands corre-
sponding to structural proteins of BLV, such as p24, gp30,
Pr45GAG, gp51, Pr70GAG, and gPr72ENV, were detected
specifically in analyses of all transfectants by Western
blotting with serum from a BLV-infected sheep (Fig. 2A).
The molecular masses of these proteins were identical
with those of proteins detected in a lysate of FLK/BLV
cells, which had been productively infected with BLV, as
a positive control. In contrast, no specific bands were
detected in analyses of all cells transfected with the
negative control vector. As shown in Fig. 2B, the RT
assay revealed that virus particles were released into the
growth medium from all cell lines after transfection with
pBLV-IF. These results suggested that pBLV-IF synthe-
sized and expressed detectable BLV proteins and that
viral particles were produced after transfection of various
cell lines. In addition, there were no intracellular obsta-
cles to the synthesis of viral RNA or protein or viral
assembly in any of the cell lines examined (Table 3).
FIG. 1. Schematic diagram of the strategy for construction of pBLV-IF
with two long terminal repeats (LTRs) from the original BLV provirus
construct pB6490, in which pX is split at an EcoRI site and there is only
one LTR. Thick lines represent BLV provirus inserts and numbers in
parentheses correspond to the nucleotide numbering of pB6490 which
is derived from that of the complete sequence of BLV (Sagata et al.,
1985). Abbreviations used for restriction enzymes: E, EcoRI; H, HindIII;
K, KpnI; P, PstI.
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FIG. 2. Biological characterization of pBLV-IF by transient transfection of various cell lines, namely, HeLa, NIH3T3, FLK, COS-1, and 23CLN.
Between 60 and 72 h after transfection with either pBLV-IF (1) or a negative control vector (2), Western blotting, RT, syncytium, and indirect
immunofluorescence (IF) analyses were performed. (A) Expression of BLV structural proteins, as shown by Western blotting with serum from
a BLV-infected sheep. FLK/BLV cells, which were productively infected with BLV, were used as the positive control. Positions of the protein
markers with molecular masses and of the BLV structural proteins are indicated. Molecular masses are in kilodaltons. (B) Viral particles
released into the growth medium from transfectants were detected by RT assay. Ten milliliters of growth media was concentrated by
ultracentrifugation and virus pellets were suspended in 50 ml of serum-free RPMI 1640 medium. Ten microliters of the concentrated preparation
of virus was then used for RT assay. (C) To examine formation of syncytia, cells were replated at 5 3 104 cells/3.5-cm-diameter dish 24 h after
transfection and cultured for an additional 2 days in complete medium supplemented with 4 mg/ml polybrene. The cells were then fixed and
stained with May–Gru¨nwald and Giemsa stains (upper). To determine whether syncytia formed in monolayers of cells that expressed BLV
antigens, cells grown on coverslips from the same dishes as those used for examination of syncytia were analyzed by indirect IF microscopy
with serum from a BLV-infected sheep (lower).
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We next investigated whether the presence of the
full-length molecular clone pBLV-IF induced the forma-
tion of syncytia, which is one of the cytopathic effects of
BLV. Five cell lines were transfected with pBLV-IF and
then the number of syncytia was counted 3 days after
transfection. The results of a typical experiment are
shown in Fig. 2C (upper). pBLV-IF induced formation of
multinucleated cells that contained, on average, 8.5, 10,
and 13.5 nuclei in HeLa, NIH3T3, and FLK cell lines,
respectively. In contrast, in COS-1 and 23CLN cells, syn-
cytia were not induced by transfection with pBLV-IF. To
further confirm the specificity of syncytia formation after
transfection with pBLV-IF, we performed indirect IF mi-
croscopy using serum from a BLV-infected sheep and
transfectants growing on coverslips. The expression of
viral antigens was specifically detected in syncytia of
HeLa, NIH3T3, and FLK cells (Fig. 2C, lower). Together,
these results demonstrated that pBLV-IF induced cyto-
pathic effects, as demonstrated by the presence of large
syncytia after transfection of HeLa, NIH3T3, and FLK
cells but not of COS-1 or 23CLN cells (Table 3).
To determine whether pBLV-IF encoded an infectious
provirus, we transfected HeLa, NIH3T3, FLK, COS-1, and
23CLN cells with either pBLV-IF or the negative control
vector, and then evaluated the kinetics of viral infection by
serially determining the percentages of cells that ex-
pressed viral antigens and the formation of syncytia in
passaged cells at 4-day intervals. As shown in Fig. 3A,
approximately 0.9–6.7% of various transfectants were pos-
itive for BLV antigens 4 days posttransfection, an indication
of the efficiency of transfection. In transfected FLK cells, the
spread of virus through the culture was rapid, with approx-
imately 35% of cells expressing viral antigens by day 20
after transfection. Similarly, only FLK cells (among the three
cell lines that formed syncytia 4 days after transfection)
exhibited an increase in the frequency of syncytia with cell
passage (Fig. 3B). Thus, the expression of BLV antigens in
FLK cells after primary and secondary infections revealed
that the full-length molecular clone pBLV-IF encoded an
infectious provirus (Table 3).
Establishment of stable BLV-transfected cell lines
To characterize the biological properties of BLV in
detail, it is essential to establish stable BLV-producing
transfectants that can produce sufficient quantities of
virus for subsequent infection experiments. Because we
detected virus particles (Fig. 2B) in the growth media of
all cells that had been transiently transfected with pBLV-
IF, we tested HeLa, NIH3T3, FLK, COS-1, and 23CLN cells
for establishment of stable transfectants with pBLV-IF.
These cell lines were transfected with linearized pBLV-IF
in combination with pBLVLTR(U3)-neo, which contained
the LTR of BLV, cloned upstream of the neomycin-resis-
tance gene, and the pSV-b-galactosidase plasmid as an
internal control for calculations of the efficiency of trans-
fections. If pBLV-IF is transcriptionally competent, then
the transactivator Tax should transactivate expression of
the neomycin-resistance gene linked to the LTR of BLV,
and cotransfection with pBLVLTR(U3)-neo and pBLV-IF
should allow the efficient cloning of BLV-producing cells.
Twenty-four hours after transfection, most of the trans-
fected cells were placed in four 10-cm-diameter dishes
in the presence of 1 mg/ml G418. An aliquot was culti-
vated for an additional 2 days for assays of b-galactosi-
dase activity. From 14 to 28 days after transfection, many
G418-resistant colonies were produced from COS-1 and
23CLN cell lines (Table 1). Several colonies within each
series of transfectants were individually expanded, and
the expression of BLV structural proteins, such as p24,
gp30, Pr45GAG, gp51, Pr70GAG, and gPr72ENV, were spe-
cifically detected in all 11 clones of COS-1 cells and in 6
of 12 clones of 23CLN cells by Western blotting. In
contrast, transfection of HeLa, NIH3T3, and FLK cells
with pBLV-IF failed to establish G418-resistant cells.
Eleven colonies of COS-1 transfectants were cloned
once by limiting dilution (Table 2). In all of 13 subclones
FIG. 3. Propagation of BLV in various cell lines after transfection with
pBLV-IF. Twenty-four hours after transient transfection with pBLV-IF,
cells were replated at 5 3 104 cells/3.5-cm-diameter dish and serially
passaged every 4 days. Cultured cells were monitored for infection at
the indicated passages by (A) indirect IF microscopy, using fixed cell
smears and serum from a BLV-infected sheep and (B) monitoring
formation of syncytia.
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derived from the COS 1, COS 5, and COS 17 clones we
detected expression of BLV antigens by Western blotting.
As judged by RT assays, five clones (COS 1.2, COS 5.2,
COS 5.3, COS 17.3, and COS 17.4) released BLV into the
growth medium in significant amounts. However, the rate
of release of BLV particles into the growth medium from
each of these clones was approximately nine to five
times lower than that from the infected cell line FLK/BLV.
Furthermore, the integration of at least one copy of the
BLV genome in the DNA of these colonies was confirmed
by Southern blotting with a 32P-labeled 6.9-kb SalI–EcoRI
fragment of the BLV proviral DNA clone. In addition, we
TABLE 1
Establishment of Cells That Stably Produced BLV after Cotransfection with pBLV-IF and pBLVLTR(U3)-neo
Cells
G418-resistant
cellsa
Efficiency of
transfection (%)b
No. of colonies expressing BLV
antigens/No. of colonies testedc
HeLa 2 1.7
NIH3T3 2 9.7
FLK 2 3.3
COS-1 1 11.4 11/11
23CLN 1 3.6 6/12
a,b pBLV-IF linearized with NotI, pBLVLTR(U3)-neo linearized with EcoRI, and the pSV-b-galactosidase vector were used to transfect cells.
Twenty-four hours posttransfection, most transfected cells were cultured in 10-cm dishes in the presence of 1 mg/ml G418 for 14 to 28 days. An aliquot
was cultivated for an additional 2 days for assays of b-galactosidase activity to determine transfection efficiencies. (1) Positive for G418-resistant
colonies; (2) negative for the same.
c Resulting clones were analyzed for production of BLV by Western blotting.
TABLE 2
Characterization of COS-1 Cells That Had Been Stably Transfected with pBLV-IF
Clone
Westerna
blotting
RT assay
(cpm)
CAT assay
(% conversion)
Southern blotting
(No. of bands)
BLV neo
COS 1 1 740 ND ND ND
1.2 1 2,065 27.1 2 2
1.4 1 NDb ND ND ND
COS 2 1 ND ND ND ND
COS 3 1 ND ND ND ND
COS 4 1 ND ND ND ND
COS 5 1 326 ND ND ND
5.1 1 ND ND ND ND
5.2 1 1,067 45.4 2 1
5.3 1 1,218 22.3 2 6
5.4 1 ND ND ND ND
5.5 1 ND ND ND ND
5.6 1 ND ND ND ND
5.7 1 ND ND ND ND
5.8 1 ND ND ND ND
COS 6 1 ND ND ND ND
COS 9 1 ND ND ND ND
COS 11 1 ND ND ND ND
COS 13 1 ND ND ND ND
COS 17 1 7,081 ND ND ND
17.3 1 1,425 98.7 1 3
17.4 1 1,743 51.5 1 3
17.5 1 ND ND ND ND
COS 19 1 ND ND ND ND
COS(2)c 2 112 1.3 0 0
FLK/BLV 1 9,826 ND ND ND
a BLV antigens were detected (1) or not detected (2) by Western blotting.
b ND, not determined.
c Parental COS-1 cells.
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confirmed the expression of Tax protein in these colo-
nies by CAT assays after transfection with the reporter
plasmid pBLTRCAT, which contains the LTR sequences
of BLV upstream of the gene for CAT.
In subsequent experiments we used COS 1.2 cells
because these cells release virus and strongly express
BLV antigens.
Cell-free transmission of BLV from BLV-producing
transfected COS-1 cells
We determined whether the virus released from COS-1
cells that had been stably transfected with pBLV-IF could
infect cell lines such as HeLa, NIH3T3, FLK, COS-1, and
23CLN by cell-free transmission (Fig. 4). The growth
medium from the stable COS 1.2 transfectant was con-
centrated by ultracentrifugation, and the suspension of
virus in serum-free RPMI 1640 was inoculated into cells
in the presence of 4 mg/ml polybrene. Three days after
inoculation, infection was monitored by RT assay of
growth media and indirect IF microscopy using serum
from a BLV-infected sheep. As shown in Fig. 4A, the RT
assay revealed that virus particles were released into the
growth medium from only FLK cells. On the other hand,
indirect IF microscopy revealed that 4.3% of FLK and
0.2% of HeLa cells expressed BLV antigens (Fig. 4B). In
contrast, the infection was not detected in NIH3T3,
COS-1, and 23CLN cells and similar results were ob-
tained even after inoculation with a very high titer of the
virus from FLK/BLV cells (data not shown). These results
indicated that, in cell-free transmission, BLV particles
from the stable COS 1.2 transfectant were able to infect
HeLa and FLK cells.
Transmission of BLV by cocultivation with BLV-
producing transfected COS-1 cells
In addition to analyzing of cell-free transmission, we
attempted to determine which cell types are infected
by cell-to-cell transmission and can serve as appro-
priate target cells for virus production. We tested the
capacity for transmission of BLV for 4 days by cocul-
tivating BLV-producing COS 1.2 cells with target cells,
such as HeLa, NIH3T3, FLK, and 23CLN cell lines. We
needed to distinguish between two types of viral trans-
mission: that occurring via contact between BLV-pro-
ducing COS 1.2 cells and uninfected target cells and
that via contact between cells which were first in-
fected by such cocultivation and uninfected target
cells. To do this, we performed three-color fluores-
cence microscopy by using serum from a BLV-infected
sheep, a monoclonal antibody against the large T
antigen of SV 40, and fluorescent dye Hoechst 33258
(Fig. 5B). The monoclonal antibody against SV 40 large
T antigen (which is constitutively expressed in nuclei
of COS-1 cells) could distinguish the syncytia pro-
duced from the fusion with COS 1.2 cells. Serum from
a BLV-infected sheep was used to investigate whether
syncytia expressed the BLV antigen. The number of
nuclei in the cell was determined after staining with
the fluorescent dye Hoechst 33258.
The cells that expressed BLV antigens exhibited
marked formation of syncytia. Syncytia of COS 1.2 cells
fused with HeLa or FLK cells simultaneously ex-
pressed BLV and SV 40 large T antigens (Fig. 5B,
upper) and were observed from the day after initiation
of cocultivation with numbers gradually increasing for
4 days (Fig. 5A). On the other hand, syncytia induced
by contact between infected and uninfected FLK cells,
which express the BLV antigens but not the SV 40
large T antigen (Fig. 5B, lower), were detected after 3
days of cocultivation, earlier than the syncytia induced
by contact of infected and uninfected HeLa cells (Fig.
5A). However, neither syncytia nor cells expressing
BLV antigens were detected in NIH3T3 and 23CLN
FIG. 4. Susceptibility of various cell lines to cell-free infection by BLV.
Concentrated cell-free preparation (RT unit 2000 cpm) of virus pro-
duced by COS-1 cells stably transfected with pBLV-IF, namely, COS 1.2
cells (1), or control medium (2) was inoculated into target cell lines
(2.5 3 105) in 10-cm-diameter dishes for 2 h at 37°C. For each inocu-
lation, cells were washed twice with RPMI 1640 after aspiration of virus
and then cultured in 10 ml of complete medium supplemented with 4
mg/ml polybrene for 3 days. Cultured cells were monitored for replica-
tion of virus as indicated by (A) RT assay for concentrated viruses that
were released into growth media and (B) indirect IF microscopy, using
fixed cell smears and serum from a BLV-infected sheep. Data shown
represent the average of two independent experiments.
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FIG. 5. Three-color fluorescence microscopy of various cell lines for examination of cell-to-cell transmission of BLV. COS-1 cells (COS 1.2, 1 3 103)
stably transfected with pBLV-IF, and target cells (5 3 104), such as HeLa, FLK, NIH3T3, and 23CLN cells, were cocultivated in 3.5-cm-diameter dishes
with coverslips. Cells grown on coverslips were incubated with monoclonal antibody against SV 40 large T antigen, PAb419, and serum from a
BLV-infected sheep. The cells were subsequently treated with FITC-conjugated F(ab9)2 of rabbit antibodies against sheep IgG and Cy3
TM-conjugated
goat antibodies against mouse IgG (H 1 L). Numbers of nuclei in cells grown on coverslips were confirmed by staining with the fluorescent dye
Hoechst 33258. Expression of SV 40 large T antigen allowed us to distinguish between two types of syncytia: those that resulted from contact of
BLV-producing COS 1.2 cells with uninfected target cells and those that resulted from contact of infected target cells with uninfected target cells.
Syncytia with nuclei positive for the SV 40 large T antigen resulted from contact between BLV-producing COS 1.2 cells and uninfected target cells,
and they expressed BLV antigens. In contrast, syncytia induced by the contact between target cells that were infected first by cocultivation with
BLV-producing COS 1.2 cells and uninfected target cells expressed BLV antigens but not the SV 40 large T antigen. (A) Histograms show specific
numbers of syncytia induced by BLV. (B) Typical fluorescence micrographs after cocultivation of COS 1.2 and HeLa or FLK cells.
59
cells during a 4-day cocultivation. Thus, BLV produced
from the stable COS 1.2 transfectant spread into FLK
and HeLa cells by cocultivation (Table 3).
DISCUSSION
In this study, we constructed pBLV-IF, an infectious
molecular clone of BLV with two LTRs. pBLV-IF allowed
us to generate stable BLV-producing transfectants that
produced virus in sufficient quantities for subsequent
infection experiments. In contrast to pB6490, which is a
covalently closed circular form of proviral DNA, pBLV-IF
is particularly useful for linearization of DNA that results
in high-efficiency integration into cells. To determine
what types of cells can serve as long-term virus-produc-
ing cells, we examined the generation of cells that pro-
duce virus efficiently using pBLV-IF. As summarized in
Table 3, cell lines that could not be isolated as clonal
colonies formed syncytia. Indeed, although most cells
died after about 7 days in G418-containing medium,
some multinucleated giant cells were found at this time
in cultures of HeLa, NIH3T3, and FLK cells. They sur-
vived for several more days but eventually failed to pro-
liferate and disappeared. These giant cells probably ex-
pressed the neo gene as well as BLV. Thus, the cyto-
pathic effect of induction of syncytia in these three cell
lines prevented clonal isolation of transfectants. In con-
trast, BLV-producing transfectants were established in
cell lines COS-1 and 23CLN that did not form syncytia
upon expression of BLV. Moreover, we developed sys-
tems in this study for transmission of BLV that was
mediated by cocultivation and cell-free inoculation using
infectious provirus produced from COS-1 cells stably
transfected with pBLV-IF. Thus, the infectious molecular
clone pBLV-IF provided a homogeneous source of infec-
tious virus, in contrast to many persistently BLV-infected
cell lines that produce defective virus particles that often
hinder subsequent analysis.
BLV produced by a stable COS-1 transfectant was able
to propagate in FLK and HeLa cells by cocultivation. In
addition to its capacity for cell-to-cell transmission, BLV
can infect cells by cell-free transmission. However, in
this study we did not examine expression in bovine
lymphoid cells transfected with pBLV-IF, although we
found that pBLV-IF could be expressed in nonlymphoid
cell lines such as HeLa, NIH3T3, FLK, COS-1, and 23CLN.
Previous studies demonstrated that transfection of pe-
ripheral blood mononuclear cells with infectious HTLV-1
molecular clones resulted in production of infectious
virus particles that induced proliferation of lymphocytes
(Kimata et al., 1994; Derse et al., 1995). However, we
recently obtained preliminary evidence that expression
of genes encoded by pBLV-IF is quite weak in several
lines of human B-lymphoid cells. Our findings are similar
to previous results (Derse, 1987) showing that when a
plasmid containing the entire BLV provirus, pBLV913,
plus pBLH2cat (that contained the LTR of BLV), was used
to cotransfect the human rhabdomyosarcoma cell line
RD-4 or the human B-lymphocyte cell line Raji, a low
level of CAT activity was detected in RD-4 cells but not in
Raji cells. Furthermore, expression of infectious HTLV-1
molecular clones in lymphoid cell lines appeared to be
restricted at the level of transcription (Kimata et al., 1994).
Indeed, expression of HTLV-1 genes is quite limited in
peripheral blood mononuclear cells of patients with adult
T-cell leukemia. Similarly, BLV is not transcribed in lym-
phocytes or tumor cells in vivo (Kettmann et al., 1980;
Gupta and Ferrer, 1982; Kettmann et al., 1982). Further-
more, viral production is low and often decreases over
time when tumors from an infected host are cultured
(Graves and Ferrer, 1976; Van der Matten and Miller,
1976). Therefore, for greater insight into the regulation of
expression of BLV genes and mechanisms of pathogen-
esis, further studies are required to clarify whether
pBLV-IF in bovine peripheral blood lymphocytes ex-
presses viral antigens and produces infectious viral par-
ticles, particularly in B lymphocytes, which are the main
target cells for infection by BLV.
The successful establishment of BLV-producing cell
lines by stable transfection with pBLV-IF allowed us to
prepare sufficient amounts of virus for cell-to-cell trans-
mission and cell-free transmission of BLV. The cells and
systems developed here may facilitate future examina-
tions of the biological and biochemical interactions of
BLV with host cells and studies of the role of individual
gene products in the life cycle or transforming potential
of BLV, as well as detailed molecular genetic studies of
the infectivity and replication of BLV.
MATERIALS AND METHODS
Constructions
A full-length infectious molecular clone of BLV, pBLV-
IF, which included two copies of an LTR, was constructed
from plasmid pB6490 (kindly provided by Dr. K. Sekikawa;
TABLE 3
Summary of BLV Interactions with Various Cell Lines
Test
Cell lines used
HeLa NIH3T3 FLK COS-1 23CLN
Transient transfection with pBLV-IF
Expression of BLV antigens 1 1 1 1 1
Release of BLV particles 1 1 1 1 1
Syncytium formation 1 1 1 2 2
Viral transmission with serial
passage 2 2 1 2 2
Establishment of stable
transfectants with pBLV-IF 2 2 2 1 1
Viral transmission by
Cell-free inoculation 1 2 1 2 2
Cocultivation 1 2 1 NDa 2
a ND, not determined.
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Itohara and Sekikawa, 1987), which has one copy of the
LTR, as follows. The numbering of nucleotides corre-
sponds to that of the complete sequence of BLV reported
by Sagata et al., (1985). First, to join the 39 portion of pX
upstream of the LTR and the 59 portion of pX of pB6490,
the 1.3-kb EcoRI–PstI fragment (positions 7925 and 1091),
containing the 39 portion of the pX region and the 39 LTR
of pB6490, was subcloned into the EcoRI and PstI sites
of pME18S, and the 3.8-kb HindIII–EcoRI fragment (posi-
tions 4118 and 7925) of pB6490 was further introduced at
the HindIII and EcoRI sites of LTRpME18S. The resulting
plasmid contained the 5.1-kb HindIII–PstI fragment, in-
cluding the complete pX region and an LTR, and was
designated pXLTRpME18S. Next, to generate the full-
length molecular clone of BLV, the 4.3-kb EcoRI–HindIII
fragment (positions 7925 and 4118) containing the LTR of
pB6490 was subcloned into the EcoRI and HindIII sites of
pBluescript II (KS2) (Stratagene, La Jolla, CA), to yield
LTR/KS, and then the 5.1-kb HindIII–KpnI fragment of
pXLTRpME18S was inserted downstream of the 4.3-kb
EcoRI–HindIII fragment of LTR/KS. The resulting plasmid
was designated pBLV-IF. This plasmid was maintained
stably in Escherichia coli XL1-Blue MRF9-competent cells
(Stratagene).
To obtain pBLVLTR(U3)-neo, in which the neomycin-
resistance gene was controlled by the LTR of BLV, we
excised the EcoRI–SacI fragment that included the U3
region of the LTR of BLV from pB6490 (positions 7925 to
261) and subcloned it into the EcoRI and SacI sites of
pUC18 to yield pUC18U3. A HindIII–BamHI fragment har-
boring neo and the SV40 polyadenylation sequences of
expression vector pMAM-neo (Clontech, Palo Alto, CA)
was also subcloned into plasmid pUC19. Furthermore, a
ScaI–HindIII fragment containing the neo and SV40 poly-
adenylation sequences of this plasmid was ligated into
the ScaI and HindIII sites of pUC18U3 to give pBLVL-
TR(U3)-neo.
To obtain the reporter plasmid pBLTRCAT, which har-
bored the LTR sequences of BLV upstream of a gene for
chloramphenicol acetyl transferase (CAT), the LTR se-
quence of l-BLV (Sagata et al., 1985) was amplified by
PCR using primers BLTRF, 59-TCCTGCAGTGTATGAAA-
GATCATGCCGCA-39 (positions 1 to 20), and BLTRR, 59-
AGTCTAGAATTGTTTGCCGGTCTCTC-39 (positions 533 to
515). The sequences that are underlined are restriction
sites for PstI and XbaI, respectively. Products amplified
by PCR were subcloned into the PstI and XbaI sites of the
pCAT-Basic vector (Promega, Madison, WI).
Cells and transfections
African green monkey kidney COS-1 cells, fetal lamb
kidney FLK cells, bovine lymph node 23CLN cells, human
cervical HeLa cells, mouse embryonic NIH3T3 cells, and
FLK/BLV cells, which are persistently infected with BLV,
were maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum, penicillin, and
streptomycin. For transient transfection, 50 mg of either
pBLV-IF or a negative control vector (pBluescript II (KS2)
was used to transfect cells (0.5–1 3 107) by electropo-
ration in a cuvette with a 0.4-cm electrode gap and a
Gene Pulser II (Bio-Rad Inc., Hercules, CA) at 240–300 V
and 975 mF. For assays of CAT activity, cells (5 3 105)
were plated in 10-cm-diameter dishes on the day before
transfection and transfected with 8 mg of pBLTRCAT plus
2 mg of the b-galactosidase expression plasmid pSV-b-
galactosidase (Promega) by the DEAE–dextran method.
Establishment of BLV-producing cell lines
To establish stable transfectants that constitutively
produced BLV, we cotransfected HeLa, NIH3T3, FLK,
COS-1, and 23CLN cells with 50 mg of pBLV-IF that had
been linearized with NotI, 5 mg of pBLVLTR(U3)-neo that
had been linearized with EcoRI, and 5 mg of pSV-b-
galactosidase vector to determine efficiencies of trans-
fection. Twenty-four hours after transfection, cells were
cultured in four 10-cm-diameter dishes in the presence of
1 mg/ml G418 (GIBCO BRL, Life Technologies, Inc., Rock-
ville, MD) for 14 to 28 days and the resulting colonies
were screened for production of BLV by Western blotting
and a reverse transcriptase (RT) assay. Then they were
cloned in 96-well plates at 0.5 cells per well.
Western blotting
Cells were lysed with a 2% solution of sodium dodecyl
sulfate (SDS) that contained 2 mM phenylmethylsulfonyl
fluoride (PMSF). The mixture was immediately boiled for
5 min. Cell lysates (20–50 mg of protein) were solubilized
in Laemmli’s buffer (Laemmli, 1970) and subjected to
SDS–PAGE on a 9% polyacrylamide gel. Then the pro-
teins on the gel were transferred electrophoretically to a
polyvinylidene difluoride membrane filter (Immobilon,
Millipore, Bedford, MA). The membrane was incubated in
buffer that contained either serum from a BLV-infected
sheep or normal sheep serum. After washing, the filter
was incubated with rabbit antibodies against sheep IgG
(Cappel, Cochranville, PA) as second antibodies and
subsequently with horseradish peroxidase-conjugated
donkey antibodies against rabbit Ig (Amersham, Little
Chalfont, Buchinghamshire, United Kingdom) as third an-
tibodies. Immunoreactive bands were visualized with
enhanced chemiluminescence (ECL) detection reagents
(Amersham).
RT assay
Growth media from cells transfected with either
pBLV-IF or the negative control vector were collected and
centrifuged at 2000 g for 10 min at 4°C and then super-
natants were filtered (0.45-mm-pore filter). Each super-
natant was layered on a cushion of 10% glycerol and
centrifuged at 20,000 rpm in an SW28 rotor (Beckman,
Palo Alto, CA) for 2 h at 4°C. Pelleted material was
resuspended in serum-free RPMI 1640 medium. Ten mi-
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croliters of the resuspended virus particles was mixed
with 30 ml of RT reaction mixture, which contained 70
mM Tris–HCl (pH 7.6), 110 mM NaCl, 13 mM dithiothreitol,
0.013% Triton X-100, 10 mM magnesium acetate, 1 mg of
poly(rA)p(dT)12–18 (Pharmacia Biotech, Uppsala, Swe-
den), and 1 mCi [3H]dTTP (NEN Research Products, Bos-
ton, MA) and incubated for 2 h at 37°C. The mixture was
applied to a DE81 filter (Whatman, Maidstone, United
Kingdom) and unincorporated [3H]dTTP was removed by
repeated washings with a 5% solution of Na2HPO4 and
methanol. The radioactivity on the filter was then quan-
titated in a liquid scintillation counter. All assays were
performed in duplicate.
Assay of CAT activity
Cells were harvested 60 h after transfection and lysed
by sonication in ice-cold 250 mM Tris–HCl (pH 7.8). To
correct the amount of extract used in the assay for
variations in the efficiency of transfection, each lysate
was assayed for b-galactosidase activity with chlorophe-
nolred-b-D-galactopyranoside (Boehringer Mannheim
GmbH, Mannheim, Germany) as a substrate. The assay
of CAT activity was performed as described by Gorman
et al., (1982). The acetylated and nonacetylated forms of
[14C]chloramphenicol (Amersham) were separated by
thin-layer chromatography on a commercial plate
(Merck, Darmstadt, Germany) and visualized and quan-
titated with an image analyzer (BAS2000; Fuji, Tokyo,
Japan).
Southern blotting
Total cellular DNA was extracted from cells trans-
fected with pBLV-IF (Hughes et al., 1978), digested with
HindIII, and then analyzed by Southern blotting (Maniatis
et al., 1982) with either the 32P-labeled 6.9-kb EcoRI–SalI
fragment of pB6490 or the 32P-labeled 3.1-kb HindIII–
BamHI fragment that harbored the neo and SV40 poly-
adenylation sequences from pMAM-neo.
Fluorescence microscopy
Cells growing on coverslips or cell smears were fixed
in a mixture of acetone and methanol (1:1, vol/vol) at
room temperature for 10 min. For detection only of ex-
pression of BLV antigens, fixed cell smears or cells on
coverslips were incubated for 30 min at room tempera-
ture with serum from a BLV-infected sheep and then
treated with fluorescein isothiocyanate (FITC)-conju-
gated rabbit antibodies against the F(ab9)2 fragment of
sheep IgG (Cappel) for 30 min. For three-color fluores-
cence microscopy, fixed cells on coverslips were first
incubated with mouse monoclonal antibody against sim-
ian virus (SV) 40 large T antigen, PAb419, and the serum
from a BLV-infected sheep for 30 min and subsequently
treated with FITC-conjugated rabbit antibodies against
the F(ab9)2 fragment of sheep IgG (Cappel) and Cy3
TM-
conjugated goat antibodies against mouse IgG (H 1 L)
(Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA). Cell nuclei were also stained with Hoechst
33258 (Sigma, St. Louis, MO). All samples were mounted
in phosphate-buffered saline (PBS) that contained 90%
glycerol and examined with a fluorescence microscope
(BX60; Olympus, Tokyo, Japan).
Assay of formation of syncytia
After transient transfection with pBLV-IF and attempts
at the cell-to-cell transmission of virus, cells growing on
3.5-cm-diameter dishes were fixed in May–Gru¨nwald’s
solution for 10 min and stained with Giemsa’s solution for
10 min. After washing with water, cells containing more
than five nuclei were counted as syncytia under a light
microscope.
Assay of b-galactosidase activity
The cells were fixed in PBS that contained 0.2% glu-
taraldehyde and 2% formaldehyde for 10 min at room
temperature and then stained with PBS that contained 1
mg/ml X-Gal (Calbiochem-Novabiochem Corp., La Jolla,
CA), 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, and 2 mM MgCl2
for 8 h at 37°C. The percentage of b-galactosidase-
positive cells was determined under an inverted light
microscope.
Serial passage of cells after transient transfection
with pBLV-IF
Twenty-four hours after transient transfection with ei-
ther pBLV-IF or the negative control vector, various lines
of cells were plated at 2.5 3 105 cells per 10-cm-diameter
dish and cultured in complete medium supplemented
with 4 mg/ml polybrene (Sigma). Culture cells were seri-
ally passaged at 4-day intervals. Aliquots of the same
cells were used for the assay of formation of syncytia
and subjected to indirect immunofluorescence (IF) mi-
croscopy using acetone–methanol-fixed smears to de-
tect infection by the virus.
Inoculation of cell-free virus
To determine whether COS-1 cells stably transfected
with pBLV-IF, namely, by COS 1.2 cells, released infec-
tious particles, the growth medium from the cells was
harvested and BLV particles were concentrated by ultra-
centrifugation as described for RT assay and resus-
pended in RPMI 1640 supplemented with 4 mg/ml poly-
brene. Then 1 ml of viral suspension (RT unit 2000 cpm)
was inoculated into various target cell lines that had
been plated at 5 3 105 cells per 10-cm-diameter dish the
day before inoculation. For each infection, cells and virus
were incubated for 2 h at 37°C, and then cells were
washed twice with RPMI 1640 after aspiration of virus
and cultured in 10 ml of complete medium supplemented
with 4 mg/ml polybrene for 3 days. The growth media
from each type of inoculated cell and the cells were
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subjected to RT assay and indirect IF microscopy, re-
spectively.
Cocultivation for cell-to-cell transmission
To measure the capacity for cell-to-cell viral transmis-
sion, COS 1.2 cells (1 3 103) and various target cell lines
(5 3 104) were cocultivated with or without sterile cov-
erslips in 3.5-cm-diameter dishes, for indicated periods
of time in complete medium supplemented with 4 mg/ml
polybrene. They were then subjected to the assay for
formation of syncytia and to three-color fluorescence
analysis using serum from a BLV-infected sheep, mono-
clonal antibody against SV40 large T antigen and
Hoechst 33258.
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